Galectin Therapeutics Inc Total Assets
Galectin Therapeutics Inc total assets. Based on the latest financial reports, Galectin Therapeutics Inc (GALT) holds total assets worth $15.76 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see GALT company net worth for the company's overall valuation and market capitalisation.
Total Assets of Galectin Therapeutics Inc (2000–2025)
Total assets of Galectin Therapeutics Inc from 2000 to 2025. This chart illustrates how Galectin Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Galectin Therapeutics Inc (GALT) stock price for real-time trading data and today's change.
Galectin Therapeutics Inc - Asset Composition Analysis
Galectin Therapeutics Inc Total Assets Breakdown (December 2025)
Galectin Therapeutics Inc total assets breakdown as of December 2025. Galectin Therapeutics Inc's total assets of $15.76 Million consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 90.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Galectin Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Galectin Therapeutics Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Galectin Therapeutics Inc's current assets represent 99.5% of total assets in 2025, an increase from 91.3% in 2000.
- Cash Position: Cash and equivalents constituted 90.7% of total assets in 2025, down from 91.3% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 8.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Galectin Therapeutics Inc Competitors by Total Assets
Key competitors of Galectin Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Galectin Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.15 | 0.08 | 5.51 |
| Quick Ratio | 2.15 | 0.08 | 5.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.38 Million | $-101.56 Million | $27.28 Million |
Galectin Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Galectin Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 207.70 |
| Latest Market Cap to Assets Ratio | 16.21 |
| Asset Growth Rate (YoY) | 11.6% |
| Total Assets | $19.53 Million |
| Market Capitalization | $316.67 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Galectin Therapeutics Inc's assets at a significant premium (16.21x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Galectin Therapeutics Inc's assets grew by 11.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Galectin Therapeutics Inc (2000–2025)
The table below shows the annual total assets of Galectin Therapeutics Inc from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $19.53 Million | +11.64% |
| 2024-12-31 | $17.50 Million | -37.96% |
| 2023-12-31 | $28.20 Million | +32.49% |
| 2022-12-31 | $21.29 Million | -49.11% |
| 2021-12-31 | $41.83 Million | +41.31% |
| 2020-12-31 | $29.60 Million | -38.93% |
| 2019-12-31 | $48.47 Million | +438.16% |
| 2018-12-31 | $9.01 Million | +116.44% |
| 2017-12-31 | $4.16 Million | -73.66% |
| 2016-12-31 | $15.79 Million | -40.19% |
| 2015-12-31 | $26.41 Million | -11.02% |
| 2014-12-31 | $29.68 Million | +177.02% |
| 2013-12-31 | $10.71 Million | +12.05% |
| 2012-12-31 | $9.56 Million | +44.60% |
| 2011-12-31 | $6.61 Million | +4.95% |
| 2010-12-31 | $6.30 Million | +1344.95% |
| 2009-12-31 | $436.00K | -38.07% |
| 2008-12-31 | $704.00K | -60.49% |
| 2007-12-31 | $1.78 Million | -71.99% |
| 2006-12-31 | $6.36 Million | +28.21% |
| 2005-12-31 | $4.96 Million | -55.33% |
| 2004-12-31 | $11.11 Million | +38.84% |
| 2003-12-31 | $8.00 Million | +250.48% |
| 2002-12-31 | $2.28 Million | +29.24% |
| 2001-12-31 | $1.77 Million | +668.06% |
| 2000-12-31 | $230.00K | -- |
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhos… Read more